Welcome to the e-CCO Library!

DOP45: Predicting late responders to filgotinib in patients with moderately to severely active Ulcerative Colitis: A post hoc analysis of SELECTION and SELECTIONLTE
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Matsuoka, K.(1)*;Löwenberg, M.(2);Fumery, M.(3);Takatori, Y.(4);Fujitani, Y.(4);Oortwijn, A.(5);Faes, M.(6);Jamoul, C.(6);Hibi, T.(7);
Created: Friday, 14 July 2023, 10:43 AM
DOP45: Utilization and sustainability of biologics in CD - A nationwide study from the epi-IIRN
Year: 2021
Source: ECCO'21 Virtual
Authors: Atia, O.(1); Yogev, D.(1);Chagit, F.(1);Gili, F.(1); Orlanski-Meyer, E.(1);Magen Rimon, R.(2);Natan, L.(3);Shira, G.(4); Kariv, R.(4);Yisca, L.W.(5); Gabay, H.(5); Nevo, D.(6); Matz, E.(7); Gorelik, Y.(8); Chowers, Y.(8);Iris, D.(9);Turner, D.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP46 Impact of a genetic burden on familial aggregation of inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

H.S. Lee1,2, L. Hannes1, M. Vancamelbeke3, V. Ballet4, M. Ferrante3,4, S. Vermeire3,4, I. Cleynen1

Created: Thursday, 30 January 2020, 10:12 AM
DOP46: Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. J. Sandborn*1, M. Ferrante2, B. R. Bhandari3, E. Berliba4, T. Hibi5, G. Geert. R. D’Haens6, J. Tuttle7, K. Krueger8, S. Friedrich8, M. Durante8, V. Arora8, B. Feagan9

Created: Friday, 22 February 2019, 9:41 AM
DOP46: Extended induction treatment with mirikizumab in patients with moderately-to-severely active ulcerative colitis: results from a phase 2 trial
Year: 2019
Source: ECCO'19 Copenhagen
Authors: William J. Sandborn
Created: Tuesday, 28 May 2019, 3:32 PM
Ulcerative colitis, Commercial
Files: 1
DOP46: Metabolic adaptation to ER stress licences STING signalling in intestinal epithelial cells
Year: 2022
Source: ECCO'22
Authors: Wottawa, F.(1);Becker, B.(2);Bakr, M.(1);Kugler, J.(1);Mayr, L.(3);Paludan, S.(4);Blumberg, R.(5);Kaser, A.(6);Adolph, T.(3);Schreiber, S.(7);Meiser, J.(2);Rosenstiel, P.(1);Aden, K.(7);
Created: Friday, 11 February 2022, 3:52 PM
DOP46: Mucosal host-microbe interactions associate with clinical phenotypes in Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Arno Bourgonje
Created: Friday, 14 July 2023, 2:22 PM
DOP46: Mucosal host-microbe interactions associate with clinical phenotypes in Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Bourgonje, A.(1)*;Hu, S.(1);Gacesa, R.(1);Jansen, B.H.(1);Björk, J.R.(1);Bangma, A.(1);Hidding, I.J.(1);van Dullemen, H.M.(1);Visschedijk, M.C.(1);Faber, K.N.(1);Dijkstra, G.(1);Harmsen, H.J.M.(2);Festen, E.A.M.(1);Vich Vila, A.(1);Spekhorst, L.M.(1);Weersma, R.K.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP46: Sustainability rate of immunomodulators monotherapy in patients with Crohn's Diseases: A population-based analysis from the epi-IIRN cohort
Year: 2021
Source: ECCO'21 Virtual
Authors: Atia, O.(1); Friss, C.(1);Mendelovici, A.(1); Shteyer, E.(1); Yogev, D.(1);Ledderman, N.(2); Greenfeld, S.(3); Kariv, R.(3); Loewenberg Weisband, Y.(4); Gabay, H.(4); Nevo, D.(5); Matz, E.(6); Dotan, I.(7);Turner, D.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP46: Tofacitinib for hospitalized acute severe Ulcerative Colitis – the TRIUMPH study
Year: 2024
Source: ECCO'24 Stockholm
Authors: Narula, Neeraj
Created: Tuesday, 30 April 2024, 5:03 PM
DOP47 The changing pattern of inflammatory bowel disease incidence in Northern France: A continuing increase in the young women (1988–2014)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. CRETIN1, H. Sarter2, G. Savoye3, M. Fumery4, A. Leroyer2, L. Dauchet2, B. Pariente5, C. Gower-Rousseau2

Created: Thursday, 30 January 2020, 10:12 AM
DOP47: Characterisation of endoscopic improvement in Crohn’s Disease with upadacitinib treatment
Year: 2024
Source: ECCO'24 Stockholm
Authors: Panaccione, Remo
Created: Tuesday, 30 April 2024, 5:03 PM
DOP47: Gut microbiome contributes to the development of immune checkpoint inhibitor-related colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Xinyu Liu
Created: Friday, 14 July 2023, 2:22 PM
DOP47: Gut microbiome contributes to the development of immune checkpoint inhibitor-related colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Liu, X.(1,2)*;Tang, H.(3);Zhou, Q.(1);Zeng, Y.(1,4);Lu, B.(1);Chen, M.(5);Xu, Y.(5);Wang, M.(5);Li, Y.(1);Tan, B.(1);Qian, J.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP47: Identification and characterization of T-cell receptor sequences associated with Crohn’s Disease
Year: 2022
Source: ECCO'22
Authors: Pesesky, M.(1);Carty, C.L.(1);Singh, N.(2);Le Bourhis, L.(3);Rosati, E.(4);Bokemeyer, B.(5);Schreiber, S.(4);Görg, S.(6);Gittelman, R.M.(1);Dines, J.N.(2);Kaplan, I.M.(7);Zahid, H.J.(8);Baldo, L.(2);Snyder, T.M.(1);Robins, H.S.(1);Franke, A.(4);Allez, M.(3);
Created: Friday, 11 February 2022, 3:52 PM
DOP47: Real World Evidence on the effectiveness of ustekinumab in Crohn’s Disease: Induction phase results from the prospective, observational RUN-CD Study
Year: 2021
Source: ECCO'21 Virtual
Authors: Bokemeyer, B.(1);Plachta-Danielzik, S.(2);Di Giuseppe, R.(3);Mohl, W.(4);Teich, N.(5);Hoffstadt, M.(6);Schweitzer, A.(7);von der Ohe, M.(8);Gauss, A.(9);Atreya, R.(10);Krause, T.(11);Blumenstein, I.(12);Höchstödter, J.(2);Hartmann , P.(1);Schreiber, S.(13)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP47: Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. Van Assche*1, S. R. Targan2, T. Baker3, C. D. O’Brien3, H. Zhang3, J. Johanns3, P. Szapary3, C. Marano3, R. W. Leong4,5, D. Rowbotham6,7, T. Hisamatsu8, S. Danese9, B. E. Sands10, L. Peyrin-Biroulet11

Created: Friday, 22 February 2019, 9:41 AM
DOP47: Sustained remission in patients with moderate to severe ulcerative colitis: Results from the phase 3 UNIFI maintenance study
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Laurent Peyrin-Biroulet
Created: Tuesday, 28 May 2019, 3:32 PM
Ulcerative colitis, Mucosal healing, Ustekinumab, Patient reported outcomes, Disease activity indices, Mucosal healing
Files: 1
DOP47: The changing pattern of Inflammatory Bowel Disease incidence in Northern France: A continuing increase in the young women (1988-2014)
Year: 2020
Source: ECCO'20 Vienna
Authors: Corinne Gower Rousseau
Created: Tuesday, 23 June 2020, 5:40 PM
DOP47: The changing pattern of Inflammatory Bowel Disease incidence in Northern France: A continuing increase in the young women (1988-2014)
Year: 2020
Source: ECCO'20 Vienna
Authors: Corinne Gower Rousseau
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1